DESIGN, DEVELOPMENT AND OPTIMIZATION OF CHEWABLE TABLET OF MONTELUKAST SODIUM
Mahendra Patel*, Revathi A. Gupta, Shivangni Rathore and Azra Shaikh
ABSTRACT
Montelukast sodium is used in the treatment of asthma. The usual dose is 4mg, 5mg and 10mg to children and adults. Now the present aim is to formulation and development of chewable tablets using different concentration of disintegrants to improve the onset of action and the bioavailability in the treatment of asthma. Montelukast sodium is a leukotriene receptor antagonist used in maintenance and treatment of asthma. Montelukast sodium chewable tablets 300mg were formulated by using different concentration of superdisintegrant croscarmellose sodium in 1 to 4% concentration. FT-IR study performed for the identification and compatibility study of drug and excipients and found that there was no characteristic change in the drug –excipients powder mixture. Hence, these excipients were selected for the formulation development. Montelukast sodium can be prepared by wet granulation method using croscarmellose sodium as superdisintegrant. Chewable tablets of Montelukast sodium with 3% of croscarmellose sodium gave better drug release of 98% with minimum disintegration time with pleasant taste. This will improve patient compliance and increase in bioavailability.
Keywords: Montelukast sodium, chewable tablets, asthma, mouth dissolving tablet, etc.
[Download Article]
[Download Certifiate]